<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-type="olc" bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public" slc-id="S1-TAM25120-MWM-D1-3R6"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 S483 IS: Responsibility in Drug Advertising Act of 2025</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2025-02-06</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><congress>119th CONGRESS</congress><session>1st Session</session><legis-num>S. 483</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date date="20250206" legis-day="20250205">February 6 (legislative day, February 5), 2025</action-date><action-desc><sponsor name-id="S363">Mr. King</sponsor> (for himself, <cosponsor name-id="S362">Mr. Kaine</cosponsor>, and <cosponsor name-id="S422">Mr. Welch</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSHR00">Committee on Health, Education, Labor, and Pensions</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title>To amend the Federal Food, Drug, and Cosmetic Act to restrict direct-to-consumer drug advertising.</official-title></form><legis-body style="OLC" display-enacting-clause="yes-display-enacting-clause" id="H7EDEB53372CF48D1925F7CF5F8820C23"><section section-type="section-one" id="H6C8047E20721480581D4CCA486BEEB45"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Responsibility in Drug Advertising Act of 2025</short-title></quote>.</text></section><section id="H5E0CAF3641764FD7A6D80639D3F056BC"><enum>2.</enum><header>Direct-to-consumer drug advertising</header><text display-inline="no-display-inline">The Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/301">21 U.S.C. 301 et seq.</external-xref>) is amended—</text><paragraph id="HB8D53F7F3EE443758433B398E707DF0F"><enum>(1)</enum><text>in section 301 (<external-xref legal-doc="usc" parsable-cite="usc/21/331">21 U.S.C. 331</external-xref>), by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="HA8E50A9B40694250B905534885A0C082"><subsection id="H130ECCDA9C3745C9B86E5241635F57CB"><enum>(jjj)</enum><text>The conduct of direct-to-consumer advertising of a drug in violation of section 506M.</text></subsection><after-quoted-block>; and</after-quoted-block></quoted-block></paragraph><paragraph id="HCCD965585EDC4F26AED6D270E2CEDB16"><enum>(2)</enum><text>in chapter V, by inserting after section 506L (<external-xref legal-doc="usc" parsable-cite="usc/21/356l">21 U.S.C. 356l</external-xref>) the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H60BE9971EA314B3A940FFC92BABC4BB9"><section id="H5F692DCBB25147DE8C3A9116932EDC42"><enum>506M.</enum><header>Direct-to-consumer drug advertising</header><subsection id="HDDDD6F2FDC1F4A8F9D15FCF64E3E6F4C"><enum>(a)</enum><header>Prohibitions</header><paragraph id="H20C078565AC849E39FEA84A15FF5E3EB"><enum>(1)</enum><header>First 3 years</header><subparagraph id="H5DF38BD94F564CDBBF97D983ADEF7ACA"><enum>(A)</enum><header>In general</header><text>Subject to subparagraph (B), no person shall conduct direct-to-consumer advertising, including on a social media platform, of a drug approved under section 505(c) before the end of the 3-year period beginning on the date of such approval.</text></subparagraph><subparagraph id="H4B330866B3484CDE879FD7A7830577B1"><enum>(B)</enum><header>Waiver</header><text>The Secretary may waive the application of subparagraph (A) to a drug during the third year of the 3-year period described in such subparagraph if—</text><clause id="H090327A18C20417987E541404C0473F6"><enum>(i)</enum><text>the sponsor of the drug submits an application to the Secretary pursuant to subparagraph (C); and</text></clause><clause id="H2A27E899A9D1484A8A0AA12DFA5F179C"><enum>(ii)</enum><text>the Secretary, after considering the application and any accompanying materials, determines that direct-to-consumer advertising of the drug would have an affirmative value to public health.</text></clause></subparagraph><subparagraph id="H3273806637674384B76EAB59CBD461FD"><enum>(C)</enum><header>Application for waiver</header><text>To seek a waiver under subparagraph (B), the sponsor of a drug shall submit an application to the Secretary at such time, in such manner, and containing such information as the Secretary may require.</text></subparagraph></paragraph><paragraph id="HEF6BDED40C924A67A67BE3CF3A0212E7"><enum>(2)</enum><header>Subsequent years</header><text>The Secretary may prohibit direct-to-consumer advertising, including on social media platforms, of a drug during the period beginning at the end of the 3-year period described in paragraph (1)(A) if the Secretary determines that the drug has significant adverse health effects based on post-approval studies, risk-benefit analyses, adverse event reports, the scientific literature, any clinical or observational studies, or any other appropriate resource.</text></paragraph></subsection><subsection id="HC4E3A16C3F464544B3ED8A1C6E29B308"><enum>(b)</enum><header>Regulations</header><text>Not later than 1 year after the date of the enactment of this section, the Secretary shall revise the regulations promulgated under this Act governing drug advertisements to the extent necessary to implement this section.</text></subsection><subsection id="H708A9C84E1714D1885C2BE9E02CCB9A2"><enum>(c)</enum><header>Rule of construction</header><text>This section shall not be construed to diminish the authority of the Secretary to prohibit or regulate direct-to-consumer advertising of drugs, including on social media platforms, under any other provision of law.</text></subsection><subsection id="HB4E39D4DE3274E6DABE7AB0E41A12769"><enum>(d)</enum><header>Effective date</header><text>This section applies only with respect to a drug approved under section 505(c) on or after the date that is 1 year before the date of enactment of this section.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></section></legis-body></bill> 

